Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy
Abstract
Tumor-infiltrating lymphocytes (TIL) are associated with benefit to trastuzumab and chemotherapy in patients with early-stage HER2+ breast cancer. The predictive value of TILs, TIL subsets, and other immune cells in patients receiving chemotherapy-sparing lapatinib plus trastuzumab treatment is unclear.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 01, 2020
- Source ID
- 10.1158/1078-0432.ccr-19-1402
Entities
People
- Aleix Prat
- Anna Tsimelzon
- Anne Pavlick
- Antonio C. Wolff
- Britta Weigelt
- Carmine De Angelis
- Carolina Gutierrez
- Chandandeep Nagi
- Charles Kent Osborne
- Cliff C. Hoyt
- Jamunarani Veeraraghavan
- Jorge S Reis-Filho
- Kristin Roman
- Linying Liu
- Maria Letizia Cataldo
- Meghana V Trivedi
- Mothaffar F Rimawi
- Paolo Nuciforo
- Rachel Schiff
- Sufeng Mao
- Susan Hilsenbeck
- Tao Wang
- Vidyalakshmi Sethunath
- Yi Zheng
Organizations
- Baylor College of Medicine
- Carlos III Health Institute
- Hospital Clinic of Barcelona
- Memorial Sloan Kettering Cancer Center
- National Institutes of Health
- The Breast Cancer Research Foundation
- United States Department of Defense
- University of Houston
- University of Naples Federico II